Antimicrobial compositions and articles comprising the compositions

By using a combination of a polycarboxylic acid chelating agent, a water-soluble polymer, and a plasticizer, the problem of low microbial treatment efficiency in existing technologies is solved, achieving effective killing of biofilms and spores, as well as long-lasting antibacterial effects on wounds and surfaces.

CN123100614APending Publication Date: 2026-11-17SOLVENTUM INTELLECTUAL PROPERTIES CO
View PDF 9 Cites 0 Cited by

Patent Information

Application Number
CN202611073863.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2019-07-29
Filing Date
2020-07-13
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies are insufficient to effectively treat and eliminate microorganisms, especially bacteria that exist in biofilms and spores, making it difficult to control hospital-acquired infections and wound infections. Furthermore, commonly used chemical treatment methods are inefficient or impractical.

Method used

A composition comprising a polycarboxylic acid chelating agent, a water-soluble or water-dispersible polymer, and a water-soluble plasticizer is used to form a flexible solid layer that can release a broad-spectrum antibacterial agent upon contact with a microbial environment, effectively killing Gram-positive bacteria, Gram-negative bacteria, and other microorganisms.

Benefits of technology

This composition effectively kills a variety of microorganisms upon contact with the microbial environment, prevents biofilm formation, reduces wound infection, prevents hospital-acquired infections, and maintains long-term antimicrobial activity on the surface.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123100614A_ABST
    Figure CN123100614A_ABST
Patent Text Reader

Abstract

This disclosure relates to antimicrobial compositions and articles comprising such compositions. Specifically, this disclosure provides a solid composition comprising a polycarboxylic acid chelating agent component mixed with a water-soluble plasticizer component, and a water-soluble or water-dispersible polymer dissolved and / or dispersed in the plasticizer component. The water-soluble plasticizer component has a boiling point >105°C and a molecular weight of less than 5000 atomic mass units. The composition contains <10% by weight of a solvent having a boiling point ≤100°C. When mixed with deionized water at a mass ratio of 1:9, the composition forms an aqueous mixture with a pH of about 2.5–5.5. The invention also provides an article comprising a substrate having a first main surface having a layer comprising the composition adhered to the first main surface. The invention further provides a method of treating biofilms or wound sites with the article.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This invention patent application is a divisional application of the invention patent application with international application number PCT / IB2020 / 056553, international application date of July 13, 2020, Chinese national phase application number 202080055075.3, and invention title "Antibacterial Composition and Article Containing the Composition". Technical Field

[0002] This disclosure relates to antimicrobial compositions and articles comprising such compositions. Specifically, this disclosure relates to articles comprising chelating compounds and antimicrobial compositions, the chelating compounds including polycarboxylic acid compounds, water-soluble or water-dispersible polymers, and water-soluble plasticizer components. Background Technology

[0003] Microorganisms are virtually ubiquitous, often in high concentrations, and are responsible for a wide range of diseases and infections. For a variety of reasons, it is necessary to kill and / or eliminate these microorganisms.

[0004] Bacteria present unique challenges because they can exist in multiple forms (e.g., plankton, spores, and biofilms), and their self-preservation mechanisms make them extremely difficult to manage and / or eradicate. For example, bacteria in biofilms or spores are downregulated (attached) and do not actively divide, which allows them to resist attacks from large amounts of antibiotics and antimicrobial agents that attack bacteria during the active parts of their life cycle (e.g., cell division).

[0005] In biofilms, bacteria interact with and attach to a surface, forming colonies that support sustained growth. Bacteria produce extracellular polysaccharides (EPS) and / or extracellular polysaccharides (ECPS) macromolecules that maintain bacterial attachment to the surface and form an effective protective barrier against various forms of attack. This protection is most likely attributed to the small diameter of flow channels in the matrix, which limits the size of molecules that can reach the underlying bacteria, and the consumption of biocides through interactions with portions of the EPS / ECPS macromolecular matrix and the bacterial secretions and waste contained therein. (Some fungi can also form biofilms, many of which present the same types of challenges as those discussed herein.)

[0006] Bacteria can also form spores, which are protein / polysaccharide shells or coatings with reduced permeability and susceptibility. Spores provide additional resistance to eradication efforts by protecting against attack from materials harmful to the bacteria.

[0007] Bacteria in these states are extremely difficult to treat due to the protection provided by their macromolecular matrix (biofilm) or shell (spore) and their downregulated state. Biocides and antimicrobial agents effective against this form of bacteria are typically gases (e.g., vapors, ethylene oxide, etc.) and strong acidic and / or oxidizing compositions, often involving halogen atoms, oxygen atoms, or both. Common examples include hypochlorite solutions (e.g., bleach), phenols, inorganic acids (e.g., HCl), H₂O₂, etc. The need for large doses of these chemicals to be effective over extended periods of time in contact with the biofilm or spores makes them impractical in many applications.

[0008] Animal tissue wounds provide a favorable environment for the growth of bacteria and even biofilms, while the surface or substrate requires gentle treatment, making an already difficult problem even more challenging.

[0009] Hospital-acquired infections (HAIs), or iatrogenic infections, can be caused by viral, bacterial, and / or fungal pathogens and may involve any system of the body. HAIs are a leading cause of death in patients and increase hospital stays, mortality rates, and healthcare costs; in developed countries, it is estimated that 5%–10% of hospitalized patients develop HAIs, with even higher rates in pediatric and neonatal patients. They are often associated with medical devices or blood transfusions. The three main sites of HAI are the bloodstream, respiratory tract, and urinary tract. Most patients with HAIs have invasive supportive measures such as central venous catheters, mechanical ventilation, and catheters, which provide entry points for pathogens. Ventilator-associated pneumonia can be caused by Staphylococcus aureus (Staphylococcus aureus). Staphylococcus aureus ), methicillin-resistant Staphylococcus aureus (MRSA), Candida albicans ( Candida albicans ), Pseudomonas aeruginosa ( Pseudomonas aeruginosa Acinetobacter baumannii ( Acinetobacter baumannii Stenotrophomonas maltophilia ( Stenotrophomonas maltophilia Clostridium difficile ( Clostridium difficile ) and Mycobacterium tuberculosis ( Mycobacterium tuberculosis This can be caused by urinary tract infections, while other HAIs include urinary tract infections, pneumonia, gastroenteritis, vancomycin-resistant enterococci (VRE), and Legionnaires' disease.

[0010] Medical devices, such as endoscopes, gastroscopes, hematology and dialysis equipment flow paths, airflow paths of respiratory equipment, ISE, HPLC, and certain catheters, are designed for multiple use. The presence of residual contamination and / or inappropriate sterilization or disinfection poses a significant risk associated with inadequate or inappropriate cleaning, up to and including HAI due to contaminated devices such as bronchoscopes contaminated with Mycobacterium tuberculosis, and the transmission of hepatitis C virus to patients during colonoscopy procedures.

[0011] Bacteria can colonize both acute and chronic wounds, and may exist in the form of spores, plankton, or biofilms. Bacterial contamination often involves multiple species. Eradicating bacteria from a wound without hindering healing can be particularly challenging.

[0012] There remains a need for compositions and products that can be used to treat microorganisms such as bacteria. Furthermore, methods and products capable of treating bacteria colonizing acute wounds at the time of injury and at all stages of healing, as well as in the treatment of chronic wounds, are also in great need. Summary of the Invention

[0013] The disclosed compositions and articles for treating or eliminating microorganisms include, but are not limited to, bacteria, whether they are in the form of planktonic organisms or biofilms, and whether they exist as a single species or as a mixed culture.

[0014] The composition and articles contain a large proportion of chelated components containing polycarboxylic acids, and still surprisingly remain brittle and even flexible.

[0015] When in contact with an aqueous environment (e.g., a wound site containing blood, serum, or wound exudate), the composition releases a solute that is lethal to a broad spectrum of Gram-positive and Gram-negative bacteria, as well as other microorganisms such as viruses, fungi, molds, and yeasts that may be present in the environment.

[0016] The present invention also provides articles and methods for treating wound areas. Articles comprising (e.g., as a layer) a solid composition can be applied to the wound area and left in place for a period of time to effectively inhibit the increase and / or reduce the number of microorganisms at the wound site. In some embodiments, the article can be temporarily applied to the wound treatment area, allowing solutes to be released into the wound environment for a period of time, and then removed.

[0017] In addition, HAI can be prevented or remedied by applying an antimicrobial composition to surfaces located in medical facilities or on the surface of medical devices to prevent or remove biofilms and / or kill bacteria adhering thereto. Patients with HAI can also be treated with an antimicrobial composition or articles containing or based on such a composition.

[0018] Additionally, the surface of permanent or removable implants can be treated to prevent biofilm formation, or post-implantation treatment can be performed to remove biofilms from such surfaces.

[0019] In one aspect, this disclosure provides a first article of article. The first article of article may include: a substrate having a first main surface and a second main surface optionally opposite the first main surface; and at least one layer adhered to the first main surface and the second main surface optionally opposite the first main surface; and at least one layer adhered to the first main surface, wherein the at least one layer comprises a composition. The composition may comprise: a dicarboxylic acid or tricarboxylic acid chelating agent component or a salt thereof mixed with a water-soluble plasticizer component; and T dissolved and / or dispersed in the plasticizer component. G A water-soluble or water-dispersible polymer with a temperature range of 20°C or higher. The composition contains at least about 10% (w / w) of a chelating agent component. The water-soluble plasticizer component has a boiling point greater than 105°C and a molecular weight less than 5000 atomic units. The composition contains less than 10% by weight of a solvent having a boiling point less than or equal to 100°C. The composition is a solid at 25°C. When mixed with deionized water at a mass ratio of 1:9, the composition forms an aqueous mixture with a pH of about 2.5-5.5.

[0020] In another aspect, this disclosure provides a second article. The second article may include: a substrate having a first main surface and optionally a second main surface opposite to the first main surface; and at least one layer adhered to the first main surface and optionally the second main surface opposite to the first main surface; and at least one layer adhered to the first main surface, wherein said at least one layer comprises a composition. The composition may comprise: a tetracarboxylic acid chelating agent component or a salt thereof mixed with a water-soluble plasticizer component; and a Tc solution dissolved and / or dispersed in the plasticizer component having a temperature greater than or equal to 20°C. G The composition is a water-soluble or water-dispersible polymer. It contains at least about 10% (w / w) of a chelating agent component. The water-soluble plasticizer component has a boiling point greater than 105°C and a molecular weight less than 5000 atomic mass units. The composition contains less than 10% by weight of a solvent having a boiling point less than or equal to 100°C. The composition is a solid at 25°C. When mixed with deionized water at a mass ratio of 1:9, the composition forms an aqueous mixture with a pH of about 2.5-5.5.

[0021] In any of the above embodiments of the first or second article, the chelating agent compound comprises an aliphatic polycarboxylic acid or a salt thereof, an aromatic polycarboxylic acid or a salt thereof, or a combination thereof. In any of the above embodiments, the at least one layer may be flexible, as defined by the ability to fold a coated film sample 180 degrees, to wrinkle it by pinching it between the thumb and forefinger, to unfold the structure, to remove a liner, and to observe that the film does not crack or peel; wherein the coated film sample comprises the at least one layer having a thickness of 150 micrometers and disposed between two cured silicone release liners, each liner having a thickness of 50 micrometers. In any of the above embodiments, the chelating agent compound may be present in the composition at most about 60% by weight. In any of the above embodiments, the plasticizer component may be present in the composition at about 15% by weight to about 75% by weight. In any of the above embodiments, the water-soluble or water-dispersible polymer may be present in the composition at about 5% by weight to about 75% by weight. In any of the above embodiments, the composition may be substantially anhydrous. In any of the above embodiments, the at least one layer may be about 50 micrometers thick to about 5000 micrometers thick. In any of the above embodiments, the article may further include a backing layer having a first side and a second side, wherein the substrate is adhered to the first side of the backing layer.

[0022] In another aspect, this disclosure provides a first method for treating biofilms or preventing biofilm formation. The first method may include contacting a tissue with at least one layer of the article of any of the above embodiments of the first or second article.

[0023] In another aspect, this disclosure provides a method for treating tissue to reduce the number of microorganisms present therein or on it. This method may include contacting the tissue with at least one layer of the article of any of the above embodiments of the first or second article.

[0024] In any of the above embodiments of the first method or the second method, contacting the tissue with the composition or article includes contacting at least one layer of the tissue with the article for about 2 hours to about 72 hours.

[0025] In another embodiment, this disclosure provides a first composition. The first composition may comprise: a dicarboxylic acid or tricarboxylic acid chelating agent component or a salt thereof, mixed with a water-soluble plasticizer component; and a Tc solution dissolved and / or dispersed in the plasticizer component having a temperature greater than or equal to 20°C. GThe first composition is a water-soluble or water-dispersible polymer. It may contain at least about 10% (w / w) of a chelating agent component. The water-soluble plasticizer component has a boiling point greater than 105°C and a molecular weight less than 5000 atomic mass units. The first composition contains less than 10% by weight of a solvent having a boiling point less than or equal to 100°C. The first composition is a solid at 25°C. When mixed with deionized water at a mass ratio of 1:9, the first composition forms an aqueous mixture with a pH of about 2.5-5.5.

[0026] In another embodiment, this disclosure provides a second composition. The second composition may comprise: a tetracarboxylic acid chelating agent component or a salt thereof mixed with a water-soluble plasticizer component; and a Tc solution dissolved and / or dispersed in the plasticizer component having a temperature greater than or equal to 20°C. G The second composition is a water-soluble or water-dispersible polymer. The second composition may contain at least about 10% (w / w) of a chelating agent component. The water-soluble plasticizer component has a boiling point greater than 105°C and a molecular weight less than 5000 atomic mass units. The second composition contains less than 10% by weight of a solvent having a boiling point less than or equal to 100°C. The second composition is a solid at 25°C. When mixed with deionized water at a mass ratio of 1:9, the second composition forms an aqueous mixture with a pH of about 2.5-5.5.

[0027] "Microorganisms (microbes)" refer to bacteria, yeast, molds, fungi, protozoa, mycoplasma, and viruses (including lipid-enveloped RNA and DNA viruses).

[0028] "Antibiotics" refers to organic chemicals prepared by microorganisms that have the ability to destroy or inhibit microorganisms in dilute concentrations and are used to treat infectious diseases. This can also encompass semi-synthetic or synthetic compounds, with semi-synthetic compounds being chemical derivatives of compounds prepared by microorganisms and synthetic compounds acting on very specific biochemical pathways necessary for cell survival.

[0029] "Antibacterial agent" refers to an antimicrobial component chemical agent that kills pathogenic and non-pathogenic microorganisms. Antimicrobial agents generally interfere more broadly with cell metabolism and / or extracellular membranes. Antimicrobial agents are sometimes referred to as disinfectants, especially when used to treat hard surfaces. Suitable antimicrobial agents include, for example: antimicrobial lipids; phenolic antimicrobial agents; cationic antimicrobial agents; iodine and / or povidone-iodine; peroxide antimicrobial agents; antimicrobial natural oils; or combinations thereof. These substances are described in US20180207122, which is incorporated herein by reference.

[0030] "Effective amount" refers to the amount of chelating agent component and / or additional antimicrobial component (when in the composition) that, overall, provides antimicrobial (including, for example, antiviral, antibacterial, or fungicidal) activity that reduces, prevents, or eliminates one or more microbial species, ultimately resulting in an acceptable level of microbial activity. Typically, this level is low enough not to cause clinical symptoms and is advantageously undetectable. It should be understood that the concentration or amount of the component in the composition (when considered separately) may not achieve an acceptable level of microbial activity, or may not kill such a broad spectrum of undesirable microorganisms, or may not kill microorganisms as rapidly; however, when used together, the aforementioned components provide enhanced (preferably synergistic) antimicrobial activity (as compared to the same component used alone under the same conditions).

[0031] "Treatment" or "treatment" refers to improving a subject's condition related to suffering, usually based on the clinical symptoms of the condition.

[0032] "Decolonization" refers to the reduction in the number of microorganisms (e.g., bacteria and fungi) present in or on tissues that do not necessarily cause immediate clinical symptoms. Examples of decolonization include, but are not limited to, decolonization in the nasal cavity and wounds. Typically, colonized tissue contains fewer microorganisms compared to infected tissue. When tissue is completely decolonized, the microorganisms have been eradicated.

[0033] "Subjects" and "patients" include humans, sheep, horses, cattle, pigs, dogs, cats, rats, mice, or other mammals.

[0034] "Pain" refers to physical symptoms caused by illness, disease, trauma, bacterial growth, etc.

[0035] A “wound” refers to trauma to a subject, involving a disruption of the normal skin barrier exposed to tissue, such as damage to subcutaneous tissues like pressure sores or poor circulation caused by tearing, surgery, or burns. Wounds are understood to include both acute and chronic wounds.

[0036] The term "comprising" and its variations are not intended to be limiting in the places where they appear in the specification and claims.

[0037] As used herein, the terms “an,” “a,” “the,” “at least one,” and “one or more” are used interchangeably. The term “and / or” refers to one or all of the listed elements (e.g., prevention and / or treatment of ailment means prevention, treatment, or both treatment and prevention of further ailment).

[0038] In addition, in this paper, the numerical range expressed by the endpoints includes all the numerical values ​​contained in that range (for example, 1 to 5 includes 1, 1.5, 2, 2.75, 3, 3.80, 4, 5, etc.).

[0039] The above description is not intended to depict every disclosed embodiment or every specific implementation of the invention. The following description illustrates exemplary embodiments in more detail. Guidance is provided at several points throughout this application by way of a list of embodiments that can be used in various combinations. In each case, the cited list is used only as a representative group and should not be construed as an exclusive list. Attached Figure Description

[0040] Figure 1A This is a plan view of one embodiment of the product according to the present disclosure.

[0041] Figure 1B yes Figure 1A An exploded side view of the product.

[0042] Figure 2A This is an exploded perspective view of an alternative embodiment of the product of manufacture according to this disclosure.

[0043] Figure 2B yes Figure 2A An exploded side view of the product. Detailed Implementation

[0044] In one aspect, this disclosure provides antimicrobial compositions that can be used to treat, eliminate, and / or prevent the colonization of microorganisms in wound sites and / or on medical devices. The compositions of this disclosure can be used to treat or prevent the colonization of wound sites or medical devices by one or more infectious microorganisms. Specifically, the compositions can be used to treat biofilms in wound sites and / or on medical devices or to prevent their formation.

[0045] Biofilms can form on any surface that is damp or becomes wet. Therefore, medical devices (e.g., catheters, stents, artificial joints, dental implants) are designed for permanent or temporary placement on or inside a patient. Extreme measures are necessary to prevent biofilm formation because once formed, they are virtually impossible to eradicate and can cause life-altering events, even fatal infections.

[0046] This composition can be used to provide effective local antimicrobial activity, thereby treating and / or preventing a variety of ailments. For example, they can be used to treat and / or prevent ailments caused or aggravated by microorganisms (e.g., Gram-positive bacteria, Gram-negative bacteria, fungi, protozoa, mycoplasma, yeast, viruses, and even lipid-enveloped viruses) on the skin and / or mucous membranes such as in the nose (anterior nasal cavity, nasopharynx, nasal cavity, etc.), external and middle ear, mouth, rectum, vagina, or other similar tissues. Particularly relevant organisms that cause or aggravate such ailments include: species of the genus Staphylococcus ( Staphylococcus spp.), species of the genus Streptococcus ( Streptococcus spp.), species of the genus *Pseudomonas* ( Pseudomonas spp.), Enterococcus species ( Enterococcus spp.) and species of the genus Escherichia ( Esherichia spp.), bacteria, and herpesviruses, Aspergillus species ( Aspergillus spp.), species of the genus Fusarium ( Fusarium spp.), species of the genus Candida ( Candida spp.) and combinations thereof. Particularly toxic organisms include: Staphylococcus aureus (including resistant strains, such as methicillin-resistant Staphylococcus aureus (MRSA), Staphylococcus epidermidis (spp.) Staphylococcus epidermidis Streptococcus pneumoniae () Streptococcus pneumoniae ), Enterococcus faecalis ( Enterococcus faecalis Vancomycin-resistant Enterococcus (VRE), Pseudomonas aeruginosa, Escherichia coli ( Escherichia coli Aspergillus niger (), Aspergillus niger Aspergillus fumigatus ( ) Aspergillus fumigatus Aspergillus lanceolata ( ) Aspergillus clavatus Fusarium solani () Fusarium solani Fusarium oxysporum ( Fusarium oxysporum ), Fusarium chlamydosporium ( Fusarium chlamydosporum Candida albicans, Candida glabrata Candida glabrata ), Candida crus-galli ( Candida krusei ), and their combinations.

[0047] The compositions can be used on a variety of surfaces. For example, they can be used on mammalian tissues (particularly skin, mucous membranes, chronic wounds, acute wounds, burns, etc.) and hard surfaces such as medical (e.g., surgical) devices, floor tiles, countertops, basins, trays, and gloves (e.g., surgical gloves). They can also be delivered by, for example, swabs, cloths, sponges, foams, nonwovens, and paper products (e.g., tissues and wipes).

[0048] It should be understood that the composition can be used in situations where there is no clinical indication for illness. For example, the composition can be used to decolonize at least a portion of acute or chronic wounds or other tissue surfaces colonized by bacteria, such as the nasal cavity (i.e., the space behind the nasal vestibule), the anterior nasal cavity (i.e., the opening in the nose leading to the nasal cavity, also known as the external nasal cavity), and / or the nasopharynx (i.e., the portion of the pharynx above the point where food enters the pharynx, i.e., the larynx), the esophagus, the vaginal cavity, etc. of a subject.

[0049] The decolonization method using the composition is particularly useful for immunocompromised patients (including cancer patients, diabetic patients, HIV patients, graft patients, etc.), and especially for fungal species such as Aspergillus and Fusarium.

[0050] Specifically, the composition can be used on chronic wounds to eliminate methicillin-resistant Staphylococcus aureus, which may or may not show clinical signs of infection, such as inflammation, pus, exudate, etc.

[0051] In some embodiments, the composition is present in large quantities over a relatively long period of time to ensure sufficient efficacy. For example, some compositions maintain antimicrobial activity at the application site for at least 4 hours, more preferably at least 8 hours, more preferably at least 24 hours, and even more preferably at least 48 hours.

[0052] In some embodiments, the composition is physically stable. A "physically stable" composition, as defined herein, is one that can be stored at 23°C for at least 3 months, and preferably at least 6 months, without significant alteration of its original state due to basic sedimentation, crystallization, phase separation, etc.

[0053] When set as a free film (i.e., not coated on a substrate) or a coating on a substrate (e.g., about 0.05 mm thick to about 5 mm thick), the solid compositions disclosed herein are flexible and deformable without causing the film or coating to break, crack, or peel off.

[0054] The compositions disclosed herein contain an effective amount of a polycarboxylic acid chelating compound. This amount is effective in preventing microbial growth and / or in effectively killing microorganisms on surfaces in contact with the composition. (A mucosal model to study microbial biofilm development and anti-biofilm therapeutics, Journal of Microbiological Methods 92 (2013) 201–208).

[0055] In some embodiments, the polycarboxylic acid chelating compound (whether aliphatic, aromatic, or a combination thereof) comprises at least two carboxylic acid groups. In some embodiments, the polycarboxylic acid chelating compound (whether aliphatic, aromatic, or a combination thereof) comprises at least three carboxylic acid groups. In some embodiments, the polycarboxylic acid chelating compound (whether aliphatic or aromatic) comprises at least four carboxylic acid groups.

[0056] Chelating compounds containing polycarboxylic acids suitable for use in the compositions of the present invention include aliphatic polycarboxylic acids, aromatic polycarboxylic acids, compounds having one or more aliphatic carboxylic acids and one or more aromatic carboxylic acids, and their salts or mixtures. Non-limiting examples of suitable chelating compounds containing polycarboxylic acids include citric acid, glutaric acid, glutamic acid, maleic acid, succinic acid, tartaric acid, malic acid, ethylenediaminetetraacetic acid, phthalic acid, trimesic acid, and pyromellitic acid.

[0057] Preferred salts include those formed from monovalent inorganic bases and include cations such as K+, Na+, Li and Ag+, and mixtures thereof. In some compositions, polyvalent bases may be suitable and include cations such as Ca++, Mg++, Zn++. Alternatively, organic bases such as primary amines, secondary amines, tertiary amines or quaternary ammonium compounds may be used to form salts of polycarboxylic acids.

[0058] Chelating compounds containing polycarboxylic acids are present in solid compositions at relatively high concentrations (by weight), yet the compositions remain surprisingly brittle. The minimum effective amount of the chelating compound in the composition is related to the number of carboxyl groups in the chelating compound. Succinic acid, having two carboxylic acids, is more effective than glutamic acid, which has the same carboxylic acid groups, because in glutamic acid, COOH is a zwitterion with -NH2.

[0059] Viscous acid is another example, containing two carboxylic acid groups but less effective than succinic acid because the COOH groups are more distant due to steric hindrance. In some embodiments, the efficacy of the composition can be improved by depositing a larger amount of the dried composition. The efficacy depends on the amount of acid in the composition and the amount of composition deposited.

[0060] Therefore, in some embodiments, the chelating agent compound comprises at least about 5% of the dry, substantially solvent-free composition by weight. In some embodiments, the chelating agent compound comprises at least about 10% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises at least about 15% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises at least about 20% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises at least about 25% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises at least about 30% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises at least about 35% of the composition by weight. In some embodiments, the chelating agent compound comprises at least about 40% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises at least about 45% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises at least about 50% of the composition by weight. In some embodiments, the chelating agent compound comprises at least about 55% of the substantially dry composition by weight.

[0061] The terms "substantially dry" or "substantially solvent-free" should be understood to mean a composition that has been treated to remove most of the solvent or has been treated in a manner that does not require solvent. This is typically a product for sale, for example, before it is applied to a patient. Generally, the solvent is a relatively volatile compound having a boiling point of less than 150°C at an ambient pressure of 760 mmHg and is used to process the composition, but is removed to obtain the final product for sale. For example, some precursor compositions are first mixed with water as a carrier to form a solution, emulsion, or dispersion. The precursor composition is coated and dried on a substrate such that the water content of the coating is less than 10% by weight, preferably less than 5% by weight, and most preferably less than 2% by weight.

[0062] In some embodiments, the chelating agent compound comprises up to about 15% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises up to about 20% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises up to about 25% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises up to about 30% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises up to about 35% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises up to about 40% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises up to about 45% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises up to about 50% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises up to about 55% of the substantially dry composition by weight. In some embodiments, the chelating agent compound comprises up to about 60% of the substantially dry composition by weight.

[0063] In some embodiments, the chelating compound containing a polycarboxylic acid comprises two aliphatic carboxylic acid groups (e.g., succinic acid), and the chelating compound accounts for at least about 10% of the substantially dry composition by weight. In some embodiments, the chelating compound containing a polycarboxylic acid comprises three aliphatic carboxylic acid groups (e.g., citric acid), and the chelating compound accounts for at least about 10% of the substantially dry composition by weight. In some embodiments, the chelating compound containing a polycarboxylic acid comprises four aliphatic carboxylic acid groups (e.g., ethylenediaminetetraacetic acid), and the chelating compound accounts for at least about 5% of the substantially dry composition by weight.

[0064] When preparing the compositions of this disclosure, a chelating compound containing a polycarboxylic acid is dissolved and / or dispersed in a water-soluble plasticizer component and optionally in a solvent such as water. The plasticizer component has a boiling point greater than 105°C and a molecular weight less than 5000 atomic mass units. Preferably, the plasticizer component is a liquid at ambient temperature (23°C). Typically, but not necessarily, the plasticizer component is the most abundant solvent in the composition in which the chelating compound containing a polycarboxylic acid is dissolved and / or dispersed. In some embodiments in which water is used to prepare the composition, substantially all of the water is subsequently removed (e.g., after the composition has been coated onto a substrate).

[0065] In some embodiments, the chelating compound comprises an aliphatic and / or aromatic polycarboxylic acid, wherein two or more carboxyl groups are available for chelation without any zwitterionic interaction. Although potential zwitterionic interactions (e.g., as in L-glutamic acid) can reduce antimicrobial efficacy compared to similar compounds that do not contain an α-amino group (e.g., glutaric acid, succinic acid), such zwitterionic compounds have been shown to exhibit antimicrobial activity in compositions according to this disclosure. Furthermore, the two or more carboxylic acid groups in the chelating compound containing the polycarboxylic acid should be disposed sufficiently close to each other in the chelating compound, or the compound should be foldable / adapted to allow the carboxylic acids to be sufficiently close to facilitate the chelation of metal ions.

[0066] In some embodiments, the chelating compound comprises an aliphatic polycarboxylic acid or a salt thereof, an aromatic polycarboxylic acid or a salt thereof, or a combination thereof. In some embodiments, the chelating compound comprises an aliphatic moiety. In some embodiments, the chelating compound comprises an aliphatic moiety. The carboxylic acid may be disposed on the aliphatic moiety and / or the aromatic moiety. Non-limiting examples of chelating compounds comprising an aliphatic moiety having a carboxylic acid group disposed thereon and an aromatic moiety having a carboxylic acid group disposed thereon include 3-(2-carboxyphenyl)propionic acid, 3-(4-carboxyphenyl)propionic acid, and 4-[(2-carboxyphenyl)amino]benzoic acid.

[0067] In some embodiments, the efficacy of the composition can be improved by depositing a larger amount of the dried composition. The efficacy depends on the amount of acid in the composition and the amount of the composition.

[0068] Suitable plasticizer components of the compositions disclosed herein include, but are not limited to, glycerol, polyglycerol having 2-20 glycerol units, polyglycerol partially esterified with C1-C18 alkyl carboxylic acids having at least two free hydroxyl groups (e.g., hexaglycerol monolaurate, decaglycerol monolaurate, polyglycerol-6 decanoate, polyglycerol-4 oleate, polyglycerol-10 trilaurate, etc.), polyethylene oxide, polyethylene glycol, polyethylene glycol initiated by any diol discussed herein such as polyethylene glycol glycerol ether, propylene glycol, dipropylene glycol, tripropylene glycol, 2-methyl-1,3-propanediol, sorbitol, dimethyl isosorbide, pentaerythritol, trimethylolpropane, bis(trimethylolpropane), random EO / PO copolymers or oligomers, block EO / PO copolymers or oligomers, and compositions of any two or more of the aforementioned plasticizer components.

[0069] The plasticizer component is present in the solid composition at a relatively high concentration (by weight). In some embodiments, the plasticizer component constitutes at least about 10% of the composition by weight. In some embodiments, the plasticizer component constitutes at least about 15% of the composition by weight. In some embodiments, the plasticizer component constitutes at least about 20% of the composition by weight. In some embodiments, the plasticizer component constitutes at least about 25% of the composition by weight. In some embodiments, the plasticizer component constitutes at least about 30% of the composition by weight. In some embodiments, the plasticizer component constitutes at least about 35% of the composition by weight. In some embodiments, the plasticizer component constitutes at least about 40% of the composition by weight. In some embodiments, the plasticizer component constitutes at least about 45% of the composition by weight. In some embodiments, the plasticizer component constitutes at least about 50% of the composition by weight. In some embodiments, the plasticizer component constitutes at least about 55% of the composition by weight. In some embodiments, the plasticizer component constitutes at least about 60% of the composition by weight. In some embodiments, the plasticizer component comprises at least about 65% of the composition by weight. In some embodiments, the plasticizer component comprises at least about 70% of the composition by weight.

[0070] In some embodiments, the plasticizer component comprises up to about 20% of the composition by weight. In some embodiments, the plasticizer component comprises up to about 25% of the composition by weight. In some embodiments, the plasticizer component comprises up to about 30% of the composition by weight. In some embodiments, the plasticizer component comprises up to about 35% of the composition by weight. In some embodiments, the plasticizer component comprises up to about 40% of the composition by weight. In some embodiments, the plasticizer component comprises up to about 45% of the composition by weight. In some embodiments, the plasticizer component comprises up to about 50% of the composition by weight. In some embodiments, the plasticizer component comprises up to about 55% of the composition by weight. In some embodiments, the plasticizer component comprises up to about 60% of the composition by weight. In some embodiments, the plasticizer component comprises up to about 65% of the composition by weight. In some embodiments, the plasticizer component comprises up to about 70% of the composition by weight. In some implementations, the plasticizer component comprises up to about 75% of the composition by weight.

[0071] In some embodiments, the plasticizer component may be used as a wetting agent. Advantageously, this maintains a moist environment in the wound to help promote wound tissue healing. In these and other embodiments, the article comprising the composition may optionally be packaged in a moisture-proof package, such as foil packaging or any non-foil moisture-proof packaging option disclosed in U.S. Patent 8,105,306, the entire contents of which are incorporated herein by reference.

[0072] Advantageously, the relatively high concentrations of plasticizers and / or water-soluble or water-dispersible polymers in the composition can be used as controlled-release modifiers, which facilitate the delivery of antimicrobial agents over extended time periods. In some embodiments, the plasticizer component can be used as the antimicrobial component.

[0073] The compositions according to the invention are solid at 25°C. In some embodiments, the composition may contain a solvent with a boiling point less than or equal to 100°C. Non-limiting examples of such solvents include water and lower (C2-C5) alcohols. Preferably, the composition contains very little solvent with a boiling point less than or equal to 100°C (e.g., less than or equal to about 10% by weight) before use. In some embodiments, the composition contains less than 5%, less than 4%, less than 3%, less than 2%, or even less than 1% (by weight) of solvent with a boiling point less than or equal to 100°C. In some embodiments, the composition may be substantially free of such solvents or any compounds with a boiling point less than 100°C (before use).

[0074] The compositions disclosed herein comprise a water-soluble or water-dispersible polymer. The water-soluble or water-dispersible polymer has a Tc greater than or equal to 20°C. G In use, this polymer can be used to form cohesive shapes in the composition, such as films, while also absorbing wound exudate and maintaining a moist environment that promotes tissue healing at the wound site.

[0075] Non-limiting examples of water-soluble or water-dispersible polymers suitable for use in compositions according to this disclosure include polyvinylpyrrolidone, polyvinyl alcohol, butanediol and vinyl alcohol and copolymers thereof, polysaccharides such as starch, guar gum, locust bean gum, carrageenan gum, hyaluronic acid, agar, alginate, tragacanth gum, gum arabic, ebony gum, gellan gum and xanthan gum, and modified forms of these polymers such as hydroxyethyl derivatives, hydroxypropyl derivatives or cationic derivatives; modified cellulose polymers (e.g., hydroxyethyl cellulose, hydroxypropyl methyl cellulose, carboxymethyl cellulose, cationic cellulose such as polyquaternium salt 4, etc.), copolymers of polyvinylpyrrolidone and vinyl acetate, water-soluble and water-swellable polyacrylates (e.g., based on hydroxyethyl acrylate, hydroxypropyl acrylate, acrylic acid, acrylamide, PEG acrylate, methyl acrylate, methacrylate, etc.), and compositions of any two or more of the aforementioned water-soluble or water-dispersible polymers. In some embodiments, the water-soluble or water-dispersible polymer may include a polyquaternium salt polymer.

[0076] In some embodiments, the water-soluble or water-dispersible polymer comprises at least about 5% of the composition by weight. In some embodiments, the water-soluble or water-dispersible polymer comprises up to about 65% of the composition by weight.

[0077] In some embodiments, the antimicrobial activity of the chelating compound can be supplemented by adding an optional antimicrobial component to the composition. Optional antimicrobial components suitable for compositions according to this disclosure include, but are not limited to, antibiotics, antimicrobial agents disclosed in US20180207122 (incorporated herein by reference), and other suitable antimicrobial agents. Preferred additional antimicrobial agents include antimicrobial lipids, phenolic antimicrobial agents, cationic antimicrobial agents, iodine and / or povidone-iodine, peroxide antimicrobial agents, antimicrobial natural oils, C6-C12 alkyldiols, silver, silver salts and complexes, silver oxide, copper, copper salts, or combinations thereof. Preferred additional antimicrobial compounds include antimicrobial quaternary ammonium compounds (e.g., benzalkonium chloride) or salts thereof, cationic surfactants (e.g., hexadecylpyridinium chloride, hexadecyltrimethylammonium bromide, etc.), polycationic compounds such as oteninidine or salts thereof, biguanide compounds (e.g., chlorhexidine, polyhexamethylene biguanide (PHMB) or salts thereof, (C6-C12) 1,2-organodiols (e.g., 1,2-octanediol), antimicrobial fatty acid monoester compounds, and combinations of any two or more of the aforementioned antimicrobial components.

[0078] In some embodiments, the use of antimicrobial quaternary ammonium compounds (e.g., benzalkonium chloride) or their salts, when added to the composition, can result in a film of superior quality compared to when they are not present.

[0079] Many compositions possess exceptional broad-spectrum antimicrobial activity and are therefore generally not terminally sterilized, but can be sterilized using various industry-standard techniques if necessary. For example, sterilization of the composition in its final packaged form using an electron beam may be preferred. Sterilization of samples by gamma radiation, nitrogen dioxide, or heat is also possible. Other sterilization methods may be acceptable. It is also suitable to include preservatives in the formulation to inhibit the growth of certain organisms. Suitable preservatives include: industry-standard compounds such as parabens (methyl, ethyl, propyl, isopropyl, isobutyl, etc.), 2-bromo-2-nitro-1,3-diol; 5-bromo-5-nitro-1,3-dioxane, chlorobutanol, diazoalkylurea; butylcarbamate iodopropyl, phenoxyethanol, halocresols, methylchloroisothiazolinone, etc., and combinations of these compounds. Antimicrobial quaternary ammonium compounds (e.g., benzalkonium chloride) or their salts, cationic surfactants (e.g., oteninidine) or their salts, biguanide compounds (e.g., PHMB) or their salts, (C6-C12) 1,2-organodiols (e.g., 1,2-octanediol), antimicrobial fatty acid monoester compounds, and combinations of any two or more of the aforementioned antimicrobial components may also act as antimicrobial agents.

[0080] The composition adheres well to mammalian tissues, particularly skin, mucous membranes, and wounds, to deliver the antimicrobial agent to the intended site over extended periods, even in the presence of sweating, drainage (e.g., mucosal secretions), or mild irrigation. In use, the composition is typically non-aqueous.

[0081] A variety of techniques can be used to deliver the composition. Typically, the composition is administered to the skin and / or mucous membrane tissue in a manner that allows the composition to penetrate the skin and / or mucous membrane tissue, rather than entering the bloodstream through the tissue. This locally concentrates the composition at the site of treatment.

[0082] When applied to a wound site, the compositions and / or articles of this disclosure are hydrated by tissue fluids and wound exudate. The compositions according to this disclosure contain a polycarboxylic acid chelating compound that exhibits antimicrobial properties at an acidic pH in an aqueous environment. Therefore, the compositions of this disclosure contain appropriate amounts of an acidic component (e.g., a free acid of the polycarboxylic acid chelating compound) and a basic component (e.g., NaOH or a salt of the polycarboxylic acid chelating compound) such that the composition, when thoroughly mixed with deionized water at a mass ratio of 1:9, forms an aqueous mixture with a pH of about 2.5 to 5.5. In some embodiments, the resulting aqueous mixture has a pH of at least 2.5. In some embodiments, the resulting aqueous mixture has a pH of at least 3.0. In some embodiments, the resulting aqueous mixture has a pH of at least 3.5. In some embodiments, the resulting aqueous mixture has a pH of at least 4.0. In some embodiments, the resulting aqueous mixture has a pH of at least 4.5. In some embodiments, the resulting aqueous mixture has a pH of at most about 3.0. In some embodiments, the pH of the resulting aqueous mixture is at most about 3.5. In some embodiments, the pH of the resulting aqueous mixture is at most about 4.0. In some embodiments, the pH of the resulting aqueous mixture is at most about 4.5. In some embodiments, the pH of the resulting aqueous mixture is at most about 5.0. In some embodiments, the pH of the resulting aqueous mixture is at most about 5.5.

[0083] A variety of other ingredients can be added to the antimicrobial composition to achieve the desired effect. These include, but are not limited to, surfactants, skin emollients and humectants (such as those described in U.S. Patent 5,951,993 (Scholz et al.), fragrances, colorants, thickeners, plasticizers, etc. Other active agents that can be used to deliver the composition to the skin include components of cosmetic compositions. These include, but are not limited to, vitamins, herbal extracts, antioxidants, steroids or other anti-inflammatory agents, vasodilators, chemokines, exfoliating agents such as alpha-hydroxy acids or beta-hydroxy acids, growth factors, enzymes, bleaching agents or colorants, emulsifiers, skin soothing agents, firming agents, anti-wrinkle agents, skin repair agents, sebum inhibitors, sebum stimulants, protease inhibitors, antipruritic ingredients, hair growth inhibitors, hair growth accelerators, skin sensitizers, anti-acne treatment agents, depilatory agents, astringents, hair removal agents, or corn, callus and wart removal agents, decorative agents such as glitter, fragrances (including aromatherapy agents and perfumes), sunscreens, insect repellents, deodorants and antiperspirants, hair dyes, bleaching agents, and anti-dandruff agents. Multiple combinations of active agents can be used in the composition.

[0084] In another aspect, this disclosure provides an article. The article comprises a solid composition made from any embodiment of the antimicrobial composition according to the invention. In some embodiments, the article comprises a film of the composition. The film may be sheet-like and optionally disposed on a surface (e.g., onto a substrate, medical dressing, or medical device as discussed herein). The article may be prepared, for example, by blending (e.g., in a homogenizer) the components and coating (e.g., by blade coating, spray coating, die coating, dip coating, curtain coating, extruding the resulting formulation onto a surface). In some embodiments, a solvent such as water may be added to the components to facilitate the coating process. Optionally, the coating formulation may be dried to remove excess water. In some embodiments where the plasticized polymer behaves as a thermoplastic, the composition may be processed using an extruder (such as a twin-screw extruder) in a solvent-free manner.

[0085] Turn to the attached diagram. Figure 1A and Figure 1B Various views of one embodiment of article 100 according to the present disclosure are shown. Article 100 includes a substrate 10 having a first main surface 12 and a second main surface 14 opposite to the first main surface. Furthermore, article 100 includes at least one layer (e.g., layer 30) adhered to the first main surface 12. In some embodiments, at least one layer 30 includes any embodiment of an antimicrobial composition according to the present disclosure. In some embodiments, at least one layer 30 consists substantially of any embodiment of an antimicrobial composition according to the present disclosure. In some embodiments, at least one layer 30 consists of any embodiment of an antimicrobial composition according to the present disclosure.

[0086] In some embodiments, at least one layer 30 is directly adhered to the substrate 10. Optionally, the article 100 may include a first adhesive 20 that adheres to at least a portion (e.g., at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100%) of the surface area of ​​the first main surface 12. Thus, in some embodiments, at least one layer 30 may adhere to the first adhesive 20. In some embodiments, at least a portion of the first adhesive 20 (e.g., portion 20a, such as...) Figure 1A (As shown in the exemplary embodiment) does not overlap with at least one layer 30. Therefore, the exposed portion 20a of the first adhesive can be used to secure the article 100 to a surface (e.g., skin adjacent to or around a wound site, not shown).

[0087] The substrate 10 may include any material suitable for medical articles. Suitable substrates include, but are not limited to, fibrous materials, foams, sheet materials, nonwoven materials, woven materials, solid polymer materials, polymer films, plastics, paper, molded fibers, rubber, glass, ceramics, metals, metal foils, the surface of medical devices, and combinations of any two or more of the aforementioned substrates. The dried composition may be placed with the substrate in any arrangement. A dry combination and a layer of fluid-absorbing material made of the same or different materials may be present. Preferably, the substrate is non-lint-free. Fluid-absorbing materials include cotton, rayon, carboxymethyl cellulose, acrylic resins, cellulose acetate, alginate, and other synthetic and natural polymers or blends. Silver-coated fibers. Today, nonwoven fiber wound dressings are more commonly used to treat highly exudative wounds. Carboxymethyl cellulose (CMC) and alginate fibers are commonly used fibers. Foam materials include polyethylene foam, cross-linked polyethylene foam, polyurethane foam, mesh polyurethane foam, melamine foam, etc.

[0088] In some embodiments, the drying composition in membrane form can be placed alone within the wound. In some embodiments, the drying composition in the form of a membrane and a fluid-absorbing material can be placed alone within the wound.

[0089] It is conceivable that when the substrate on which the composition is disposed is part of a medical device (e.g., a catheter), the first primary surface on which the composition is disposed (e.g., as a coating) may be a wavy surface (i.e., not necessarily a generally flat surface), and the substrate may not include a second primary surface opposite to the first primary surface.

[0090] In some embodiments, the substrate is porous prior to coating. It is conceivable that the compositions of this disclosure can be disposed on the surface of the porous substrate and within the pores (e.g., at least partially within the pores), and can extend completely through the pores.

[0091] In some implementations, medical tape or transparent adhesive dressings can be used to attach articles comprising a porous substrate to a patient (e.g., at a wound site).

[0092] Figure 2A and Figure 2B An alternative embodiment of the article 200 comprising a porous substrate is shown. Article 200 comprises as described above for... Figures 1A to 1BThe article 100 comprises a substrate 10, an optional first adhesive 20, and at least one layer 30. Furthermore, the article 200 includes a backing layer 50 having a first side 52 and a second side 54 opposite to the first side. Additionally, a second main surface 14 of the substrate 10 (e.g., via an optional second adhesive 40) is adhered to the first side 52 of the backing layer 50. The optional second adhesive 20 adheres to at least a portion of the first side 52 of the backing layer 50 (e.g., at least 5%, at least 10%, at least 20%, at least 30%, at least 40%, at least 50%, at least 60%, at least 70%, at least 80%, at least 90%, or 100% of the surface area). In some embodiments, at least a portion of the second adhesive 40 (not shown) does not overlap with the substrate 10. Therefore, exposed portions of the second adhesive can be used to secure the article 200 to a surface (e.g., skin adjacent to or surrounding a wound site, not shown).

[0093] The backing layer is preferably a barrier against liquids and bacteria, but is a highly moisture-permeable membrane, such as that described in U.S. Patents 3,645,835 and 4,595,001, the disclosures of which are incorporated herein by reference. In one embodiment, the backing layer is composed of an elastomeric polyurethane, polyester, or polyether block amide membrane. These membranes combine the desired properties of resilience, elasticity, high moisture permeability, and transparency. A description of such characteristics of the materials used to construct the backing layer can be found in published U.S. Patents 5,088,483 and 5,160,315, the disclosures of which are incorporated herein by reference. Commercially available examples of potentially suitable sheet materials for the backing layer may include thin polymer film backings sold under trade names such as TEGADERM (3M Company) and OPSITE (Smith & Nephew Company). Many other backing materials may also be used, including those commonly used in the manufacture of surgical drapes (e.g., surgical drapes manufactured by 3M under the trade names STERIDRAPE and IOBAN), as described in U.S. Patent 5,985,395, the entire contents of which are incorporated herein by reference.

[0094] In some embodiments, the substrate on which the composition is disposed as a layer (e.g., a polymer film, a woven material, or a nonwoven material) is flexible. Therefore, an article comprising a substrate having a flexible layer on which the composition of this disclosure is disposed can be advantageously applied to and adapted to the shape of irregular (e.g., curved, angular, pitted, uneven) surfaces that may be present on a patient's body or medical device. In some embodiments, the composition layer disposed on the substrate of the article is at least as flexible as the substrate of the article.

[0095] In some embodiments, at least one layer of a substantially dry antimicrobial composition coated with a relatively thin layer (e.g., less than about 5 mm, less than about 4 mm, less than about 3 mm, less than about 2 mm, or less than about 1 mm) is substantially optically transparent and advantageously allows observation and inspection of objects disposed beneath the layer (e.g., wound tissue, medical devices). Transparency is an indicator of the compatibility of the composition components and can be assessed by applying the composition to a suitable flat release liner, drying the composition, and evaluating the percentage of transmittance. This is described in the examples. For meaningful comparisons, the composition should be applied to an optically flat release liner at a specified thickness, dried appropriately, and kept dry prior to testing. Compatibility and transparency can be affected by a variety of factors, including pH, which determines the degree of ionization of the chelating agent, the addition of surfactants (such as those disclosed in U.S. Patent 8,512,723, which is incorporated herein by reference, and antimicrobial surfactants such as benzalkonium chloride, hexadecylpyridinium chloride, etc.), and the type and amount of plasticizers. Finally, film thickness and film roughness can affect transmittance%, so the film should be kept relatively thin, for example <5 mm, and an optically flat pad is preferred.

[0096] In some embodiments, the substrate (e.g., a polymer film) on which the composition is disposed as a layer is substantially optically transparent. Therefore, an article comprising an optically transparent substrate on which an optically transparent layer of the disclosed composition is disposed (e.g., coated) advantageously provides visual inspection of objects disposed beneath the article (e.g., wound tissue, medical devices). Preferred compositions allow caregivers to observe wounds and apply dressings containing the composition to the wounds without removing the dressings. Preferred dressings are transparent both initially and after absorption of clear wound fluid.

[0097] In some embodiments, the article forming the sheet or layer (e.g., less than about 3 mm, less than about 2 mm, less than about 1 mm, less than about 0.5 mm, or less than about 0.5 mm) is flexible (i.e., capable of conforming to irregular surfaces without breaking and / or peeling to the extent that it causes the sheet or layer to disintegrate). Advantageously, this allows the article to be applied to irregular surfaces (e.g., curved, angled, pitted, uneven) that may be present on a patient's body or medical device.

[0098] In some embodiments, the compositions according to this disclosure may be disposed (e.g., as a layer or coating) on ​​a medical device. Medical devices include those on which microorganisms may form colonies or biofilms when the medical device is placed on or inside a patient. Non-limiting examples of such medical devices include intravenous or urinary catheters, cannulas, tracheostomy cannulas, stoma flanges, stoma rings, and stoma bags.

[0099] The compositions are flexible during coating and drying, meaning that when the test is performed immediately after drying, the film of one of these compositions will not break or shatter when it is bent, and the film remains in membrane form.

[0100] On the other hand, this disclosure provides methods for treating biofilms or preventing the formation of biofilms (e.g., in wound sites or on medical devices).

[0101] From a microbiological perspective, the primary function of normal, intact human and animal skin is to control the microbial community living on its surface and to prevent potential pathogens from colonizing and invading the underlying tissues. Exposure to subcutaneous tissue (i.e., wounds) provides a moist, warm, and nutrient-rich environment conducive to microbial colonization and proliferation. Because wound colonization is largely multimicrobial, involving many potentially pathogenic microorganisms, any wound carries a risk of infection. If a wound infection fails to heal, the patient suffers increased trauma and higher treatment costs.

[0102] Most wound infections are caused by Staphylococcus aureus (20%), Staphylococcus epidermidis (14%), Enterococcus species (12%), Escherichia coli (8%), Pseudomonas aeruginosa (8%), and Enterobacter species ( Enterobacter spp. (7%), Proteus species ( Proteus spp. (3%), Klebsiella pneumoniae ( Klebsiella pneumoniae (3%), Streptococcus ( Streptococci (3%) and Candida albicans (3%). Wound healing and infection are influenced by the relationship between the ability of bacteria to establish stable communities in the wound environment and the host's ability to control the bacterial community. Because bacteria can rapidly form their own protective microenvironment (biofilm) after attaching to a surface, the host's ability to control these organisms may decrease as the biofilm community matures. Within a stable biofilm community, interactions between aerobic and anaerobic bacteria may increase their net pathogenicity, thereby enhancing their likelihood of causing infection and delaying healing.

[0103] The methods according to this disclosure include contacting tissue with any embodiment of the composition according to this disclosure. Contacting tissue with the composition may also include covering the composition and tissue with a protective layer (e.g., tape, dressing).

[0104] Alternatively, the method according to this disclosure includes contacting an organization with an article comprising any embodiment of a composition according to this disclosure. The article comprising the composition may also include a substrate, wherein the composition is disposed as a layer on and / or within a substrate as disclosed herein.

[0105] In some embodiments, contacting tissue with the composition includes contacting the wound site (e.g., acute wound, chronic wound, surgical wound, site of percutaneous insertion of a medical device such as a needle or thread) with the composition.

[0106] In some embodiments, contacting tissue with an article containing the composition (e.g., a medical device coated with the composition) includes contacting the tissue with the medical device containing the composition. Alternatively, the composition may be applied directly to the medical device and dried. Non-limiting examples of such medical devices include intravenous or urinary catheters, cannulas, tracheostomy cannulas, nasogastric tubes, surgical instruments (including but not limited to colonoscopes, cystoscopes, laparoscopes, bronchoscopes, etc.), stoma flanges, stoma gaskets, stoma bags, and oral implants.

[0107] Contacting tissue with the composition or an article containing the composition (e.g., as a coating) includes contacting the tissue with the composition for a period of time. This period of time is preferably from about 0.5 hours to about 72 hours.

[0108] In some preferred embodiments, an article (e.g., a film or a coated substrate) is attached to a wound fluid-absorbing material (e.g., a medical dressing), and then the wound fluid-absorbing material is placed on the wound site.

[0109] The following examples further illustrate the purpose and advantages, but the specific substances and amounts listed in these examples, as well as other conditions and details, should not be construed as an undue limitation of the invention.

[0110] Example

[0111] Material

[0112] Table 1. Materials used in the examples

[0113] Test methods for antimicrobial activity against biofilms: In vitro biofilm assay of porcine mucosal tissue

[0114] Tissue preparation: Porcine vaginal mucosal tissue was trimmed in vitro and transferred to RPMI 1640 medium + 5% penicillin / streptomycin solution (part number P4458, from Sigma-Aldrich, St. Louis, MO). Biopsy tissue perforations (5 mm diameter) were prepared to obtain explants for this assay. Most of the remaining muscle tissue was removed using a new surgical blade. The explants were rinsed three times with 10 ± 2 ml of RPMI (antibiotic-free, fetal bovine serum-free). The explants were covered with fresh medium in a 37°C incubator for approximately 30 minutes. Six-well plates were prepared in wells using 2.0 ± 0.5 ml of RPMI (antibiotic-free, fetal bovine serum-free), and transwell chambers were placed in each well. The tissue explants were transferred to the transwell chambers mucosal-side up (3 explants / well).

[0115] Bacterial Preparation: Biofilm-producing strains of *Pseudomonas aeruginosa* were used in these experiments. Fresh agar cultures of each bacterial strain were prepared from frozen stock solutions over a two-week experimental period. Several colonies were inoculated into culture tubes containing Todd Hewitt fermentation broth and incubated overnight in a shaking incubator (37±2°C, 200±50 rpm). A 1±0.1 mL fraction of the overnight culture was transferred to a sterile microcentrifuge tube. The microcentrifuge tube was centrifuged (at maximum speed for 1±0.5 min) to precipitate the bacteria. The precipitate was washed with 1±0.1 mL RPMI (ABX-free, FCS-free). After washing, the precipitate was resuspended in 1±0.1 mL of fresh RPMI. A 300±20 µl fraction of the resuspended cells was diluted in 5±0.5 mL of fresh RPMI. The resulting diluted bacterial suspension (2 ± 1 µl for each explant) was added to each transwell chamber, and the 6-well plate was returned to the incubator at 37 °C for 2 ± 0.5 hours to infect the explants.

[0116] Treatment: The antimicrobial composition (a 10mm × 10mm dried antimicrobial membrane described below) was applied directly to the mucosal tissue (explant) inoculated with microorganisms. After applying the dried membrane, the microplate was incubated at 37±2℃ for 24±4 hours.

[0117] Sampling: Transfer explants to 250±20µL of standard sampling solution and vortex mix for 30±10 seconds. Briefly sonicate to disrupt cell aggregates, then vortex mix again for 30±10 seconds. Store a portion of the resulting sonicated material at 4°C. Inoculate another portion of the sonicated material at an appropriate dilution onto bromophthalimide trimethylammonium selective agar, incubate overnight, and count the colonies. If the initial colony count is too high to count, further dilute the refrigerated portion of the sonicated material, spread it onto bromophthalimide trimethylammonium agar, incubate, and count the colonies after incubation.

[0118] Examples 1-12. Antimicrobial compositions containing glycerol as a water-soluble plasticizer component. .

[0119] Preparation of the composition : Prepare all compositions in 100g amounts according to the formulations listed in Table 2. Prepare a mixture of L-PVPK60 (47% by weight aqueous solution). All compositions shown in Table 2, in addition to the components listed in the table, contain 50g of the aforementioned aqueous mixture of L-PVPK60. For each composition, add all ingredients except L-PVPK60 to a MAX 100 cup (Flacktec Inc.; Landrum, SC, South Carolina, USA) and use a DAC 400 FVZ SpeedMixer. ™ The instrument (Flacktec, Inc.) was used to mix at 3500 rpm for 1 minute. Subsequently, 50 g of the L-PVPK60 aqueous mixture was added to the cup and mixed again at 3500 rpm for 1 minute.

[0120] Preparation of articles containing the composition: On the same day, each composition was prepared as described above. The viscous composition was scraped onto a release liner using gaps of 127 μm, 254 μm, 381 μm, 508 μm, 635 μm, 762 μm, 1016 μm, and 1270 μm, respectively, to prepare films of various thicknesses. The coatings were dried in a convection oven at 80°C for 10 minutes to remove substantially all water from the coatings. The dried antimicrobial films were peeled off from the liner, and the antimicrobial activity of the antimicrobial films was tested as described above. The results of the antimicrobial tests are shown in Table 3.

[0121] Table 2. Components of the antimicrobial compositions in Examples 1-13 .

[0122]

[0123] 1 – 50% (w / w) NaOH aqueous solution

[0124] Table 3: Antimicrobial activity of the compositions in Examples 1-12. According to the methods described herein, this was achieved by analyzing logs of live bacteria prior to exposure to the composition. 10 Number minus log of live bacteria after exposure to the composition 10 The number is used to calculate the logarithmic decrease value (LRV).

[0125]

[0126] The data in Table 3 show that each composition containing various polycarboxylic acid chelating compounds exhibits bactericidal activity against the microorganisms used in the biofilm test model.

[0127] Comparative Examples 1-4. Effect of the concentration of chelating compounds containing polycarboxylic acids .

[0128] Preparation of the composition : Prepare all compositions in 100g amounts according to the formulations listed in Table 4. Prepare a mixture of L-PVPK60 (47% by weight aqueous solution). All compositions shown in Table 4, in addition to the components listed in the table, contain 50g of the aforementioned aqueous mixture of L-PVPK60. For each composition, add all ingredients except L-PVPK60 to a MAX 100 cup (Flacktec Inc.; Landrum, SC, South Carolina, USA) and use a DAC 400 FVZ SpeedMixer. ™ The instrument (Flacktec, Inc.) was used to mix at 3500 rpm for 1 minute. Subsequently, 50 g of the L-PVPK60 aqueous mixture was added to the cup and mixed again at 3500 rpm for 1 minute.

[0129] Articles of each composition (i.e., films coated on the pads) were prepared as described in Examples 1-12, and their antimicrobial activity was tested as described above. Was pH measured? The results of the antimicrobial tests are shown in Table 5.

[0130] Table 4. Components of the compositions of Comparative Examples 1-4 .

[0131]

[0132] Table 5. Antimicrobial activity of the compositions of Comparative Examples 1-4. Log reduction value (LRV) was calculated as described above.

[0133]

[0134] The data in Table 5 show that each composition containing various relatively low concentrations of polycarboxylic acid chelating agent compounds did not exhibit significant bactericidal activity against the microorganisms used in the biofilm test model.

[0135] Examples 13-19. Antimicrobial compositions comprising various water-soluble plasticizer components .

[0136] Preparation of the composition : Prepare all compositions in 100g amounts according to the formulations listed in Table 6. Prepare a mixture of L-PVPK60 (47% by weight aqueous solution). All compositions shown in Table 6, in addition to the components listed in the table, contain 50g of the aforementioned aqueous mixture of L-PVPK60. For each composition, add all ingredients except L-PVPK60 to a MAX 100 cup (Flacktec Inc.; Landrum, SC, South Carolina, USA) and use a DAC 400 FVZ SpeedMixer. ™ The instrument (Flacktec, Inc.) was used to mix at 3500 rpm for 1 minute. Subsequently, 50 g of the L-PVPK60 aqueous mixture was added to the cup and mixed again at 3500 rpm for 1 minute.

[0137] Articles of each composition (i.e., films coated on the pads) were prepared as described in Examples 1-12, and their antimicrobial activity was tested as described above. The results of the antimicrobial tests are shown in Table 7.

[0138] Table 6. Components of the antimicrobial compositions of Examples 13-19 .

[0139]

[0140] Table 7. Antimicrobial activity of the compositions of Examples 13-19. Logarithmic reduction value (LRV) was calculated as described above.

[0141]

[0142] The data in Table 7 show that each composition containing various polycarboxylic acid chelating compounds exhibits bactericidal activity against the microorganisms used in the biofilm test model.

[0143] Flexibility and optical transparency test

[0144] The following compositions were tested for flexibility and transmittance (%):

[0145] Flexibility Test: To obtain the membrane's flexibility, immediately after mixing the components as described above, coat the membrane to a thickness of approximately 0.15 mm onto a 50-micron thick UV-cured silicone-coated liner. Dry the membrane at 80°C for 10–20 minutes, then remove it from the oven and allow it to reach room temperature. Immediately test the flexibility in an indoor environment with a temperature of 22°C and a relative humidity of 66%. Place an additional liner on top of the film and cut a 10.16 cm × 25.4 cm sheet of film with liners on both sides. Fold the sheet approximately in half at a 180-degree angle and crease it once by running an adult male's middle finger along the crease. Afterward, unfold the membrane along with the liners on both sides, remove the top liner, and visually inspect the membrane for any breaks, cracks, or peeling. No visible breaks, cracks, or peeling of the membrane is considered a pass.

[0146] Transmittance Testing: To obtain the transmittance % of the membrane, immediately after mixing the components as described above, coat the membrane onto the backing. Dry the membrane at 80°C for 10–20 minutes, then remove it from the oven and allow it to reach room temperature. Immediately test the transmittance % in an indoor environment with a temperature of 22°C and a relative humidity of 63%. Place the additional backing on top of the membrane and cut a 10.16 cm × 10.16 cm sheet of membrane with backing on both sides. After removing the backing from one side of the membrane and placing a slide on it, place a 7.62 cm × 5.08 cm, 1.016 mm thick slide on the membrane. To measure the transmittance %, peel the backing off from the other side and place the slide with the membrane vertically behind a cuvette in a Hewlett Packard 8453 UV-VIS spectrophotometer. Record readings at three different locations on the membrane and report the values ​​as transmittance %.

[0147] All patents, patent documents, and published disclosures cited herein are incorporated herein by reference in their entirety as if each document were cited separately. Various modifications and alterations will be apparent to those skilled in the art without departing from the scope and spirit of the invention. It should be understood that the invention is not intended to be unduly limited to the exemplary embodiments and examples shown herein, and that these embodiments and examples are merely illustrative; the scope of the invention is intended to be limited only by the claims shown below.

Claims

1. An article comprising: A substrate having a first main surface and optionally a second main surface opposite to the first main surface; and At least one layer adhered to the first main surface, the at least one layer comprising a composition. The composition comprises: A dicarboxylic acid or tricarboxylic acid chelating agent component or a salt thereof, said dicarboxylic acid or tricarboxylic acid chelating agent component having aromatic regions and aliphatic regions, wherein the carboxylic acid is disposed on said aromatic regions, said aliphatic regions or any combination thereof, and A water-soluble plasticizer component, characterized by having a boiling point greater than 105°C and a molecular weight less than 5000 atomic mass units, and T dissolved and / or dispersed in the plasticizer component G a water-soluble or water-dispersible polymer greater than or equal to 20°C, and An antimicrobial surfactant, wherein the antimicrobial surfactant is selected from benzalkonium chloride, cetylpyridinium chloride, or mixtures thereof; The chelating agent component is present in an amount of at least 10% (w / w). The composition contains less than 10% by weight (w / w) of a solvent, said solvent being characterized by having a boiling point of less than or equal to 100°C. The composition is solid at 25°C, and When mixed with deionized water at a mass ratio of 1:9, the composition forms an aqueous mixture with a pH of 2.5-5.

5.

2. An article comprising: A substrate having a first main surface and optionally a second main surface opposite to the first main surface; and At least one layer adhered to the first main surface, the at least one layer comprising a composition. The composition comprises: A tetracarboxylic acid chelating agent component or a salt thereof, said tetracarboxylic acid chelating agent component having aromatic regions and aliphatic regions, wherein the carboxylic acid is disposed on said aromatic regions, said aliphatic regions, or any combination thereof. A water-soluble plasticizer component, characterized by having a boiling point greater than 105°C and a molecular weight less than 5000 atomic units. T dissolved and / or dispersed in the plasticizer component G Water-soluble or water-dispersible polymers at or above 20°C, and An antimicrobial surfactant, wherein the antimicrobial surfactant is selected from benzalkonium chloride, cetylpyridinium chloride, or mixtures thereof; The chelating agent component is present in an amount of at least 5% (w / w). The composition contains less than 10% by weight of a solvent, wherein the solvent is characterized by having a boiling point of less than or equal to 100°C. The composition is solid at 25°C, and When mixed with deionized water at a mass ratio of 1:9, the composition forms an aqueous mixture with a pH of 2.5-5.

5.

3. The article according to claim 1 or 2, wherein the chelating agent compound is selected from 3-(2-carboxyphenyl)propionic acid, 3-(4-carboxyphenyl)propionic acid and 4-[(2-carboxyphenyl)amino]benzoic acid.

4. The article according to claim 1 or 2, wherein the water-soluble or water-dispersible polymer is selected from polyvinylpyrrolidone, polyvinyl alcohol, butanediol and vinyl alcohol and their copolymers, polysaccharides, modified cellulose polymers, copolymers of polyvinylpyrrolidone and vinyl acetate, water-soluble or water-swellable polyacrylates, and any combination of two or more of the aforementioned water-soluble or water-dispersible polymers, and combinations thereof.

5. The article according to claim 1 or 2, wherein the water-soluble or water-dispersible polymer is polyvinylpyrrolidone.

6. The article according to claim 1 or 2, wherein the water-soluble or water-dispersible polymer is polyvinylpyrrolidone, and the water-soluble plasticizer is glycerol.

7. The article according to claim 1 or 2, wherein the plasticizer component is selected from glycerol, polyglycerol having 2-20 glycerol units, polyglycerol partially esterified with a C1-C18 alkyl carboxylic acid having at least two free hydroxyl groups, polyethylene oxide, polyethylene glycol, propylene glycol, dipropylene glycol, tripropylene glycol, 2-methyl-1,3-propanediol, sorbitol, pentaerythritol, trimethylolpropane, bis(trimethylolpropane), random EO / PO copolymers or oligomers, and block EO / PO copolymers or oligomers.

8. The article of claim 1 or 2, wherein one or more of the following are included: The chelating compound is present in the composition in up to 60% by weight; The plasticizer component is present in the composition at a concentration of 10% to 75% by weight; The water-soluble or water-dispersible polymer is present in the composition at a concentration of 5% to 65% by weight.

9. The article of claim 1 or 2, wherein the composition further comprises an antimicrobial component selected from antibiotics, antimicrobial quaternary ammonium compounds or salts thereof, biguanide compounds or salts thereof, (C6-C12)1,2-organodiols, antimicrobial fatty acid monoester compounds, cationic surfactants, and combinations thereof.

10. The article of claim 1 or 2, wherein the layer has a transmittance of greater than 5% at 550 nm when tested according to a transparency test.

11. The article of claim 1 or 2, wherein the at least one layer is 50 micrometers to 5000 micrometers thick.

12. The article of claim 1 or 2, wherein the substrate is at least a portion of a medical device selected from: catheters, cannulas, tracheostomy cannulas, stoma flanges, stoma rings, stoma bags, and oral implants.

13. A method for treating a biofilm or preventing biofilm formation, the method comprising contacting a tissue with at least one layer of the article according to any one of claims 1 or 2.

14. A method of treating tissue to reduce the number of microorganisms present in or on said tissue, the method comprising contacting said tissue with at least one layer of an article of claim 1 or 2.

15. A composition comprising: A dicarboxylic acid or tricarboxylic acid chelating agent component or a salt thereof, wherein the dicarboxylic acid or tricarboxylic acid chelating agent component has aromatic regions and aliphatic regions, wherein the carboxylic acid is disposed on the aromatic regions, the aliphatic regions, or any combination thereof. The dicarboxylic acid or the tricarboxylic acid chelating agent component or its salt is present in an amount of at least 10% (w / w) of the composition; or A tetracarboxylic acid chelating agent component or a salt thereof, said tetracarboxylic acid chelating agent component having aromatic regions and aliphatic regions, wherein the carboxylic acid is disposed on said aromatic regions, said aliphatic regions, or any combination thereof. The tetracarboxylic acid chelating agent component or its salt is present in an amount of at least 5% (w / w) of the composition; A water-soluble or water-dispersible polymer, wherein the water-soluble or water-dispersible polymer has a Tc greater than or equal to 20°C. G ;and A water-soluble plasticizer component, said water-soluble plasticizer component having a boiling point greater than 105°C and a molecular weight less than 5000 atomic mass units; and An antimicrobial surfactant, wherein the antimicrobial surfactant is selected from benzalkonium chloride, cetylpyridinium chloride, or mixtures thereof; The composition wherein the composition contains less than 10% by weight of a solvent, and the solvent has a boiling point of less than or equal to 100°C; The composition is a solid at 25°C; When mixed with deionized water at a mass ratio of 1:9, the composition forms an aqueous mixture with a pH of 2.5-5.5.

Citation Information

Patent Citations

  • Methods of reducing microbial contamination

    US20180207122A1

  • Moisture-vapor-permeable pressure-sensitive adhesive materials

    US3645835A

  • Surgical adhesive dressing

    US4595001A

  • Adhesive frame bandage

    US5088483A

  • Combined adhesive strip and transparent dressing delivery system

    US5160315A